Symbols / XERS
XERS Chart
About
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 1.11B |
| Enterprise Value | 1.27B | Income | -15.64M | Sales | 266.14M |
| Book/sh | -0.01 | Cash/sh | 0.55 | Dividend Yield | — |
| Payout | 0.00% | Employees | 394 | IPO | — |
| P/E | — | Forward P/E | 21.18 | PEG | — |
| P/S | 4.15 | P/B | -1332.00 | P/C | — |
| EV/EBITDA | 45.46 | EV/Sales | 4.79 | Quick Ratio | 1.25 |
| Current Ratio | 1.93 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -0.10 | EPS next Y | 0.31 | EPS Growth | — |
| Revenue Growth | 37.10% | Earnings | 2026-03-02 | ROA | 2.88% |
| ROE | — | ROIC | — | Gross Margin | 84.56% |
| Oper. Margin | 9.05% | Profit Margin | -5.88% | Shs Outstand | 165.92M |
| Shs Float | 157.32M | Short Float | 10.64% | Short Ratio | 7.50 |
| Short Interest | — | 52W High | 10.08 | 52W Low | 3.58 |
| Beta | 0.93 | Avg Volume | 2.00M | Volume | 1.16M |
| Target Price | $11.14 | Recom | None | Prev Close | $6.68 |
| Price | $6.66 | Change | -0.30% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$11.14
Mean price target
2. Current target
$6.66
Latest analyst target
3. DCF / Fair value
$3.10
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$6.66
Low
$8.00
High
$18.00
Mean
$11.14
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-09 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2025-12-09 | init | Barclays | — → Overweight | $9 |
| 2025-11-07 | main | Oppenheimer | Outperform → Outperform | $18 |
| 2025-11-07 | main | HC Wainwright & Co. | Buy → Buy | $10 |
| 2025-11-07 | main | Piper Sandler | Neutral → Neutral | $8 |
| 2025-10-29 | main | Oppenheimer | Outperform → Outperform | $18 |
| 2025-09-17 | main | HC Wainwright & Co. | Buy → Buy | $10 |
| 2025-08-19 | main | Leerink Partners | Outperform → Outperform | $9 |
| 2025-08-08 | main | Craig-Hallum | Buy → Buy | $11 |
| 2025-08-08 | main | Oppenheimer | Outperform → Outperform | $8 |
| 2025-06-05 | main | Leerink Partners | Outperform → Outperform | $7 |
| 2025-05-09 | main | Oppenheimer | Outperform → Outperform | $7 |
| 2025-03-07 | reit | Piper Sandler | Neutral → Neutral | $4 |
| 2025-03-07 | main | Leerink Partners | Outperform → Outperform | $6 |
| 2025-03-07 | main | Craig-Hallum | Buy → Buy | $7 |
| 2025-03-07 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2025-01-29 | reit | Jefferies | Buy → Buy | $6 |
| 2024-11-11 | main | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-11-11 | down | Piper Sandler | Overweight → Neutral | $3 |
| 2024-08-15 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
- Xeris Biopharma Holdings, Inc. (XERS) Stock Analysis: Unveiling a Promising 65% Potential Upside - DirectorsTalk Interviews Sat, 21 Feb 2026 07
- Xeris Biopharma sets March 2 call on 2025 results, 2026 view - Stock Titan ue, 17 Feb 2026 12
- What Makes Xeris Biopharma (XERS) a Strong Momentum Stock: Buy Now? - Yahoo Finance ue, 09 Sep 2025 07
- How XERS Company (XERS) Affects Rotational Strategy Timing - Stock Traders Daily Sat, 21 Feb 2026 21
- Gen Xers share 17 nostalgic dishes they ate growing up—and still make for dinner - Upworthy Sun, 22 Feb 2026 18
- XERS Crosses Below Key Moving Average Level - Nasdaq hu, 19 Feb 2026 16
- $XERS stock is down 16% today. Here's what we see in our data. - Quiver Quantitative hu, 06 Nov 2025 08
- Xeris Biopharma: Strong Recorlev Momentum And Pipeline Opportunity (XERS) - Seeking Alpha ue, 03 Feb 2026 08
- Risks Still Elevated At These Prices As Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Shares Dive 35% - simplywall.st Wed, 03 Dec 2025 08
- Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year - Yahoo Finance Sun, 09 Nov 2025 08
- $XERS stock is up 14% today. Here's what we see in our data. - Quiver Quantitative hu, 08 Jan 2026 08
- Xeris Biopharma (Nasdaq: XERS) receives USPTO Notice of Allowance for XP-8121 - Stock Titan Mon, 01 Dec 2025 08
- Xeris Biopharma: A Balanced Perspective Needed (Rating Downgrade) - Seeking Alpha hu, 18 Dec 2025 08
- Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Analysts Are Pretty Bullish On The Stock After Recent Results - simplywall.st Sun, 10 Aug 2025 07
- Xeris Biopharma (XERS) Reports Break-Even Earnings for Q3 - Yahoo Finance hu, 06 Nov 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 16667 | 124147 | — | Sale at price 7.45 per share. | HECHT BETH P | Officer | — | 2026-02-02 00:00:00 | D |
| 1 | 121293 | — | — | Stock Award(Grant) at price 0.00 per share. | HECHT BETH P | Officer | — | 2026-01-30 00:00:00 | D |
| 2 | 478436 | — | — | Stock Award(Grant) at price 0.00 per share. | SHANNON JOHN PATRICK JR | Chief Executive Officer | — | 2026-01-30 00:00:00 | D |
| 3 | 154986 | — | — | Stock Award(Grant) at price 0.00 per share. | PIEPER STEVEN | Chief Financial Officer | — | 2026-01-30 00:00:00 | D |
| 4 | 168463 | — | — | Stock Award(Grant) at price 0.00 per share. | MCCULLOCH KEVIN | President | — | 2026-01-30 00:00:00 | D |
| 5 | 121293 | — | — | Stock Award(Grant) at price 0.00 per share. | NGUYEN ANH TU | Officer | — | 2026-01-30 00:00:00 | D |
| 6 | 15000 | 120000 | — | Sale at price 8.00 per share. | MCCULLOCH KEVIN | President | — | 2026-01-08 00:00:00 | D |
| 7 | 24907 | 176257 | — | Sale at price 7.08 per share. | SHANNON JOHN PATRICK JR | Chief Executive Officer | — | 2026-01-05 00:00:00 | D |
| 8 | 92301 | 149998 | — | Conversion of Exercise of derivative security at price 1.55 - 3.94 per share. | SHANNON JOHN PATRICK JR | Chief Executive Officer | — | 2026-01-05 00:00:00 | D |
| 9 | 16667 | 123776 | — | Sale at price 7.43 per share. | HECHT BETH P | Officer | — | 2026-01-02 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 67.76K | 46.50K | -38.83K | 0.00 |
| TaxRateForCalcs | 0.04 | 0.02 | 0.01 | 0.00 |
| NormalizedEBITDA | -15.70M | -26.10M | -66.69M | -112.96M |
| TotalUnusualItems | 1.71M | 2.36M | -2.62M | -702.00K |
| TotalUnusualItemsExcludingGoodwill | 1.71M | 2.36M | -2.62M | -702.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -54.84M | -62.26M | -94.66M | -122.72M |
| ReconciledDepreciation | 12.62M | 13.16M | 12.67M | 1.88M |
| ReconciledCostOfRevenue | 35.05M | 26.33M | 20.81M | 11.99M |
| EBITDA | -13.99M | -23.73M | -69.31M | -113.67M |
| EBIT | -26.62M | -36.90M | -81.98M | -115.55M |
| NetInterestIncome | -25.16M | -21.86M | -11.52M | -6.87M |
| InterestExpense | 30.48M | 26.61M | 14.10M | 7.18M |
| InterestIncome | 5.32M | 4.75M | 2.58M | 313.00K |
| NormalizedIncome | -56.47M | -64.57M | -92.08M | -122.02M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -54.84M | -62.26M | -94.66M | -122.72M |
| TotalExpenses | 236.72M | 207.92M | 192.19M | 164.75M |
| TotalOperatingIncomeAsReported | -33.65M | -44.01M | -81.94M | -115.16M |
| DilutedAverageShares | 146.77M | 137.67M | 135.63M | 79.03M |
| BasicAverageShares | 146.77M | 137.67M | 135.63M | 79.03M |
| DilutedEPS | -0.37 | -0.45 | -0.70 | -1.55 |
| BasicEPS | -0.37 | -0.45 | -0.70 | -1.55 |
| DilutedNIAvailtoComStockholders | -54.84M | -62.26M | -94.66M | -122.72M |
| NetIncomeCommonStockholders | -54.84M | -62.26M | -94.66M | -122.72M |
| NetIncome | -54.84M | -62.26M | -94.66M | -122.72M |
| NetIncomeIncludingNoncontrollingInterests | -54.84M | -62.26M | -94.66M | -122.72M |
| NetIncomeContinuousOperations | -54.84M | -62.26M | -94.66M | -122.72M |
| TaxProvision | -2.27M | -1.25M | -1.42M | 0.00 |
| PretaxIncome | -57.10M | -63.50M | -96.08M | -122.72M |
| OtherIncomeExpense | 1.71M | 2.36M | -2.62M | -702.00K |
| SpecialIncomeCharges | 1.70M | 2.36M | -4.38M | 0.00 |
| OtherSpecialCharges | 2.69M | 2.84M | 1.22M | |
| RestructuringAndMergernAcquisition | -4.39M | -5.20M | 3.16M | 0.00 |
| GainOnSaleOfSecurity | 8.00K | 1.00K | 1.76M | -702.00K |
| NetNonOperatingInterestIncomeExpense | -25.16M | -21.86M | -11.52M | -6.87M |
| TotalOtherFinanceCost | 2.69M | |||
| InterestExpenseNonOperating | 30.48M | 26.61M | 14.10M | 7.18M |
| InterestIncomeNonOperating | 5.32M | 4.75M | 2.58M | 313.00K |
| OperatingIncome | -33.65M | -44.01M | -81.94M | -115.16M |
| OperatingExpense | 199.88M | 179.28M | 169.55M | 151.43M |
| DepreciationAmortizationDepletionIncomeStatement | 10.84M | 10.84M | 10.84M | 550.00K |
| DepreciationAndAmortizationInIncomeStatement | 10.84M | 10.84M | 10.84M | 550.00K |
| Amortization | 10.84M | 10.84M | 10.84M | 550.00K |
| AmortizationOfIntangiblesIncomeStatement | 10.84M | 10.84M | 10.84M | 550.00K |
| ResearchAndDevelopment | 25.56M | 22.34M | 20.97M | 25.16M |
| SellingGeneralAndAdministration | 163.48M | 146.09M | 137.75M | 125.72M |
| GrossProfit | 166.24M | 135.27M | 87.61M | 36.27M |
| CostOfRevenue | 36.83M | 28.64M | 22.63M | 13.32M |
| TotalRevenue | 203.07M | 163.91M | 110.25M | 49.59M |
| OperatingRevenue | 203.07M | 163.91M | 110.25M | 49.59M |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 149.43M | 138.13M | 136.27M | 124.87M |
| ShareIssued | 149.43M | 138.13M | 136.27M | 124.87M |
| NetDebt | 160.49M | 123.48M | 65.11M | 20.80M |
| TotalDebt | 271.45M | 229.19M | 198.06M | 88.07M |
| TangibleBookValue | -151.40M | -139.41M | -98.28M | -59.08M |
| InvestedCapital | 202.49M | 184.15M | 232.26M | 183.30M |
| WorkingCapital | 67.22M | 61.07M | 113.20M | 63.56M |
| NetTangibleAssets | -151.40M | -139.41M | -98.28M | -59.08M |
| CapitalLeaseObligations | 39.34M | 38.26M | 10.98M | 0.00 |
| CommonStockEquity | -29.61M | -6.78M | 45.19M | 95.23M |
| TotalCapitalization | 187.39M | 184.15M | 232.26M | 183.30M |
| TotalEquityGrossMinorityInterest | -29.61M | -6.78M | 45.19M | 95.23M |
| StockholdersEquity | -29.61M | -6.78M | 45.19M | 95.23M |
| GainsLossesNotAffectingRetainedEarnings | -25.00K | -25.00K | -23.00K | -31.00K |
| OtherEquityAdjustments | -25.00K | -25.00K | -23.00K | -31.00K |
| RetainedEarnings | -671.86M | -617.02M | -554.77M | -460.11M |
| AdditionalPaidInCapital | 642.26M | 610.25M | 599.97M | 555.36M |
| CapitalStock | 15.00K | 14.00K | 14.00K | 13.00K |
| CommonStock | 15.00K | 14.00K | 14.00K | 13.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 352.68M | 329.38M | 299.33M | 209.13M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 252.23M | 234.19M | 225.71M | 130.09M |
| OtherNonCurrentLiabilities | 1.97M | 6.23M | 25.72M | 30.20M |
| NonCurrentDeferredLiabilities | 0.00 | 2.27M | 3.52M | 11.82M |
| NonCurrentDeferredTaxesLiabilities | 0.00 | 2.27M | 3.52M | 4.94M |
| LongTermDebtAndCapitalLeaseObligation | 250.26M | 225.70M | 196.48M | 88.07M |
| LongTermCapitalLeaseObligation | 33.26M | 34.76M | 9.40M | 0.00 |
| LongTermDebt | 217.01M | 190.93M | 187.07M | 88.07M |
| CurrentLiabilities | 100.44M | 95.19M | 73.62M | 79.04M |
| OtherCurrentLiabilities | 1.09M | 20.28M | 2.66M | 1.99M |
| CurrentDebtAndCapitalLeaseObligation | 21.18M | 3.50M | 1.58M | |
| CurrentCapitalLeaseObligation | 6.08M | 3.50M | 1.58M | 0.00 |
| CurrentDebt | 15.10M | |||
| OtherCurrentBorrowings | 15.10M | |||
| PensionandOtherPostRetirementBenefitPlansCurrent | 19.58M | 16.96M | 13.40M | 19.64M |
| CurrentProvisions | 19.08M | 14.20M | 11.17M | 4.00M |
| PayablesAndAccruedExpenses | 39.51M | 40.27M | 44.81M | 53.41M |
| CurrentAccruedExpenses | 37.22M | 28.70M | 40.20M | 44.49M |
| InterestPayable | 2.12M | 1.37M | 4.66M | 1.41M |
| Payables | 2.29M | 11.56M | 4.61M | 8.92M |
| AccountsPayable | 2.29M | 11.56M | 4.61M | 8.92M |
| TotalAssets | 323.06M | 322.60M | 344.52M | 304.36M |
| TotalNonCurrentAssets | 155.40M | 166.34M | 157.70M | 161.76M |
| OtherNonCurrentAssets | 5.41M | 4.54M | 4.73M | 829.00K |
| GoodwillAndOtherIntangibleAssets | 121.78M | 132.62M | 143.47M | 154.31M |
| OtherIntangibleAssets | 98.92M | 109.76M | 120.61M | 131.45M |
| Goodwill | 22.86M | 22.86M | 22.86M | 22.86M |
| NetPPE | 28.21M | 29.18M | 9.51M | 6.63M |
| AccumulatedDepreciation | -7.26M | -6.04M | -5.53M | -4.13M |
| GrossPPE | 35.47M | 35.21M | 15.04M | 10.76M |
| Leases | 6.06M | 5.98M | 5.07M | 5.03M |
| OtherProperties | 4.73M | 4.15M | 3.84M | 3.74M |
| MachineryFurnitureEquipment | 2.04M | 1.87M | 2.14M | 2.00M |
| BuildingsAndImprovements | 22.65M | 23.20M | 3.99M | 0.00 |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 167.66M | 156.26M | 186.82M | 142.60M |
| OtherCurrentAssets | 7.45M | 5.78M | 9.29M | 4.59M |
| PrepaidAssets | 4.59M | |||
| Inventory | 48.17M | 38.84M | 24.73M | 18.12M |
| FinishedGoods | 5.45M | 10.47M | 5.96M | 5.50M |
| WorkInProcess | 10.99M | 10.96M | 11.37M | 7.44M |
| RawMaterials | 31.73M | 17.40M | 7.41M | 5.18M |
| Receivables | 40.41M | 39.20M | 30.83M | 17.46M |
| AccountsReceivable | 40.41M | 39.20M | 30.83M | 17.46M |
| CashCashEquivalentsAndShortTermInvestments | 71.62M | 72.45M | 121.97M | 102.43M |
| OtherShortTermInvestments | 0.00 | 5.00M | 0.00 | 35.16M |
| CashAndCashEquivalents | 71.62M | 67.45M | 121.97M | 67.27M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -37.85M | -49.29M | -103.42M | -96.62M |
| RepurchaseOfCapitalStock | -3.73M | -1.01M | -468.00K | -534.00K |
| RepaymentOfDebt | -11.83M | 0.00 | -44.23M | 0.00 |
| IssuanceOfDebt | 50.00M | 0.00 | 146.21M | 0.00 |
| IssuanceOfCapitalStock | 0.00 | 0.00 | 30.00M | 27.00M |
| CapitalExpenditure | -868.00K | -2.26M | -524.00K | -1.08M |
| InterestPaidSupplementalData | 26.95M | 27.69M | 10.86M | 7.29M |
| EndCashPosition | 75.74M | 71.67M | 126.31M | 67.27M |
| BeginningCashPosition | 71.67M | 126.31M | 67.27M | 37.60M |
| EffectOfExchangeRateChanges | 0.00 | 0.00 | -3.00K | |
| ChangesInCash | 4.07M | -54.64M | 59.04M | 29.68M |
| FinancingCashFlow | 36.17M | -1.61M | 127.47M | 27.25M |
| CashFlowFromContinuingFinancingActivities | 36.17M | -1.61M | 127.47M | 27.25M |
| NetOtherFinancingCharges | -1.19M | -4.88M | -54.00K | |
| ProceedsFromStockOptionExercised | 1.73M | 581.00K | 836.00K | 835.00K |
| NetCommonStockIssuance | -3.73M | -1.01M | 29.53M | 26.47M |
| CommonStockPayments | -3.73M | -1.01M | -468.00K | -534.00K |
| CommonStockIssuance | 0.00 | 0.00 | 30.00M | 27.00M |
| NetIssuancePaymentsOfDebt | 38.17M | 0.00 | 101.98M | 0.00 |
| NetLongTermDebtIssuance | 38.17M | 0.00 | 101.98M | 0.00 |
| LongTermDebtPayments | -11.83M | 0.00 | -44.23M | 0.00 |
| LongTermDebtIssuance | 50.00M | 0.00 | 146.21M | 0.00 |
| InvestingCashFlow | 4.88M | -6.00M | 34.46M | 97.96M |
| CashFlowFromContinuingInvestingActivities | 4.88M | -6.00M | 34.46M | 97.96M |
| NetInvestmentPurchaseAndSale | 5.75M | -3.74M | 34.98M | 60.58M |
| SaleOfInvestment | 40.24M | 40.00M | 34.98M | 103.60M |
| PurchaseOfInvestment | -34.48M | -43.74M | 0.00 | -43.02M |
| NetBusinessPurchaseAndSale | 0.00 | 0.00 | 38.47M | |
| SaleOfBusiness | 0.00 | 0.00 | 38.47M | |
| CapitalExpenditureReported | -868.00K | -2.26M | -524.00K | -1.08M |
| OperatingCashFlow | -36.98M | -47.02M | -102.89M | -95.53M |
| CashFlowFromContinuingOperatingActivities | -36.98M | -47.02M | -102.89M | -95.53M |
| ChangeInWorkingCapital | -8.82M | -6.29M | -35.15M | 11.85M |
| ChangeInOtherWorkingCapital | 3.81M | 6.42M | 9.68M | -77.00K |
| ChangeInOtherCurrentLiabilities | 1.08M | 818.00K | -6.18M | 0.00 |
| ChangeInPayablesAndAccruedExpense | -2.04M | 6.43M | -13.93M | 22.30M |
| ChangeInAccruedExpense | 7.57M | -524.00K | -9.61M | 16.77M |
| ChangeInPayable | -9.61M | 6.96M | -4.32M | 5.53M |
| ChangeInAccountPayable | -9.61M | 6.96M | -4.32M | 5.53M |
| ChangeInPrepaidAssets | -1.67M | 3.21M | -3.89M | 3.29M |
| ChangeInInventory | -8.78M | -14.80M | -7.46M | -7.42M |
| ChangeInReceivables | -1.22M | -8.37M | -13.37M | -6.24M |
| ChangesInAccountReceivables | -1.22M | -8.37M | -13.37M | -6.24M |
| OtherNonCashItems | -1.38M | -3.00M | 3.63M | 961.00K |
| StockBasedCompensation | 18.36M | 10.72M | 12.16M | 11.38M |
| AmortizationOfSecurities | -747.00K | -1.26M | 184.00K | 413.00K |
| DeferredTax | -2.27M | -1.25M | -1.42M | 0.00 |
| DeferredIncomeTax | -2.27M | -1.25M | -1.42M | 0.00 |
| DepreciationAmortizationDepletion | 12.62M | 13.16M | 12.67M | 1.88M |
| DepreciationAndAmortization | 12.62M | 13.16M | 12.67M | 1.88M |
| AmortizationCashFlow | 10.84M | 10.84M | 10.84M | 550.00K |
| AmortizationOfIntangibles | 10.84M | 10.84M | 10.84M | 550.00K |
| Depreciation | 1.78M | 2.32M | 1.82M | 1.33M |
| OperatingGainsLosses | 83.00K | 3.16M | -301.00K | 702.00K |
| GainLossOnInvestmentSecurities | -8.00K | -1.00K | -1.76M | 702.00K |
| GainLossOnSaleOfPPE | 91.00K | 321.00K | 236.00K | 0.00 |
| NetIncomeFromContinuingOperations | -54.84M | -62.26M | -94.66M | -122.72M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for XERS
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|